Why Is Penny Stock ProKidney Trading Higher On Tuesday?
1. ProKidney reported positive Phase 2 trial results for rilparencel in CKD patients. 2. Rilparencel showed a 78% improvement in eGFR decline in Group 1. 3. FDA Type B meeting scheduled for accelerated approval strategy confirmation. 4. PROK stock surged 56.6% during premarket trading on positive news. 5. No serious adverse events reported in the trial participants.